- Data show control of acute myeloid leukemia by a
trifunctional NKp46-CD16a-NK cell engager targeting CD123
- These results support clinical development of CD123-NKCE; A
Phase 1/2 clinical trial by Sanofi is ongoing
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate”
or the “Company”) announced today the publication in Nature
Biotechnology of preclinical data showing the control of acute
myeloid leukemia (AML) cells by a trifunctional NKp46-CD16a-NK cell
engager (NKCE) targeting CD123. The studies were conducted by
Innate and Sanofi and published in Nature Biotechnology on January
12, 2023.
The study shows that expression of CD64 on AML blasts confers
resistance to anti-CD123 antibody-dependent cell cytotoxicity
(ADCC) and redirecting NK cells against cancer targets through
binding to CD16a and NKp46 circumvents this resistance. Moreover,
through their binding to NKp46, CD123-NKCE specifically target NK
cells and has potent antitumor activity against primary AML blasts;
it induces NK cell activation and cytokine secretion only in the
presence of AML cells. In vivo, its antitumor activity in a mouse
tumor model exceeds that of the comparator anti-CD123 antibody. The
efficacy of CD123-NKCE in vitro in human peripheral blood
mononuclear cells and in vivo in nonhuman primates was associated
with the induction of low pro-inflammatory cytokine release and no
signs of toxicity.
These results support clinical development of CD123-NKCE. A
Phase 1/2 clinical trial by Sanofi is ongoing, evaluating
IPH6101/SAR’579 (SAR443579), the first NKp46/CD16-based
CD123-targeted ANKETTM NK cell engager, in patients with relapsed
or refractory acute myeloid leukemia (R/R AML), B-cell acute
lymphoblastic leukemia (B-ALL) or high-risk myelodysplastic
syndrome (HR-MDS).
Eric Vivier, DVM, PhD, Chief Scientific Officer of Innate
Pharma:
“The activity, safety, pharmacokinetic and pharmacodynamics data
provided here demonstrate the superiority of CD123-NKCEs over
comparator cytotoxic antibodies in terms of antitumor activity, and
their favorable safety profiles relative to T cell therapies for
the treatment of AML. IPH6101/SAR’579 is a multi-specific NKCE
targeting CD123 currently in a Phase 1 trial in AML sponsored by
Sanofi. At Innate Pharma, we are developing a broad portfolio of NK
Cell Engager programs via our proprietary platform ANKETTM that can
address different types of cancer.”
Valeria Fantin, Ph.D., Global Head of Oncology Research at
Sanofi:
“At Sanofi, we are building a diverse oncology portfolio
including next-generation NK-based assets and bringing new
approaches to fighting cancer. We're pleased with our productive
collaboration with Innate Pharma, and data like this reinforce our
confidence in proceeding to clinical evaluation of this novel NK
cell engager."
About ANKETTM
ANKETTM (Antibody-based NK cell Engager Therapeutics) is
Innate's proprietary platform for developing next-generation,
multi-specific natural killer (NK) cell engagers to treat certain
types of cancer.
This versatile, fit-for-purpose technology is creating an
entirely new class of molecules to induce synthetic immunity
against cancer. It leverages the advantages of harnessing NK cell
effector functions against cancer cells and also provides
proliferation and activation signals targeted to NK cells.
Our latest innovation, the tetra-specific ANKET molecule, is the
first NK cell engager technology to engage activating receptors
(NKp46 and CD16), a tumor antigen and an interleukin-2 receptor
(via an IL-2 variant, IL-2v) via a single molecule.
About Innate Pharma
Innate Pharma S.A. is a global, clinical-stage oncology-focused
biotech company dedicated to improving treatment and clinical
outcomes for patients through therapeutic antibodies that harness
the immune system to fight cancer.
Innate Pharma’s broad pipeline of antibodies includes several
potentially first-in-class clinical and preclinical candidates in
cancers with high unmet medical need.
Innate is a pioneer in the understanding of Natural Killer cell
biology and has expanded its expertise in the tumor
microenvironment and tumor-antigens, as well as antibody
engineering. This innovative approach has resulted in a diversified
proprietary portfolio and major alliances with leaders in the
biopharmaceutical industry including Bristol-Myers Squibb, Novo
Nordisk A/S, Sanofi, and a multi-products collaboration with
AstraZeneca.
Headquartered in Marseille, France with a US office in
Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq
in the US.
Learn more about Innate Pharma at www.innate-pharma.com
Information about Innate Pharma shares:
ISIN code
FR0010331421
Ticker code
Euronext: IPH Nasdaq: IPHA
LEI
9695002Y8420ZB8HJE29
Disclaimer on forward-looking information and risk
factors:
This press release contains certain forward-looking statements,
including those within the meaning of the Private Securities
Litigation Reform Act of 1995. The use of certain words, including
“believe,” “potential,” “expect” and “will” and similar
expressions, is intended to identify forward-looking statements.
Although the company believes its expectations are based on
reasonable assumptions, these forward-looking statements are
subject to numerous risks and uncertainties, which could cause
actual results to differ materially from those anticipated. These
risks and uncertainties include, among other things, the
uncertainties inherent in research and development, including
related to safety, progression of and results from its ongoing and
planned clinical trials and preclinical studies, review and
approvals by regulatory authorities of its product candidates, the
Company’s commercialization efforts, the Company’s continued
ability to raise capital to fund its development and the overall
impact of the COVID-19 outbreak on the global healthcare system as
well as the Company’s business, financial condition and results of
operations. For an additional discussion of risks and uncertainties
which could cause the company's actual results, financial
condition, performance or achievements to differ from those
contained in the forward-looking statements, please refer to the
Risk Factors (“Facteurs de Risque") section of the Universal
Registration Document filed with the French Financial Markets
Authority (“AMF”), which is available on the AMF website
http://www.amf-france.org or on Innate Pharma’s website, and public
filings and reports filed with the U.S. Securities and Exchange
Commission (“SEC”), including the Company’s Annual Report on Form
20-F for the year ended December 31, 2021, and subsequent filings
and reports filed with the AMF or SEC, or otherwise made public, by
the Company.
This press release and the information contained herein do not
constitute an offer to sell or a solicitation of an offer to buy or
subscribe to shares in Innate Pharma in any country.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230115005038/en/
For additional information:
Investors
Innate Pharma Henry Wheeler Tel.: +33 (0)4 84 90 32 88
Henry.wheeler@innate-pharma.fr
Media Relations
NewCap Arthur Rouillé Tel.: +33 (0)1 44 71 00 15
innate@newcap.eu
Innate Pharma (EU:IPH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Innate Pharma (EU:IPH)
Historical Stock Chart
From Sep 2023 to Sep 2024